Latest News and Press Releases
Want to stay updated on the latest news?
-
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today...
-
CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome...
-
Eterna Therapeutics announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101.
-
CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of...
-
Eterna Launches Research to Evaluate its Lead iMSC Therapy Candidate’s Ability to Induce and Modulate Antitumor Immunity in Ovarian and Breast Models
-
Eterna Therapeutics Announces $1 Million Stock Repurchase Program
-
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
-
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
-
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license...
-
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line